Floatz logo

Ruxolitinib

Chronic Myelogenous Leukemia

Center for International Blood and Marrow Transplant ResearchSmall moleculePhase 2Active
B
63/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
53/ 100
Competitive Position
81/ 100

Competitive context

85 Active assets in the Chronic Myelogenous Leukemia cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
City of Hope Medical Center
Phase 3BBB
Nilotinib
Novartis Pharmaceuticals
Phase 4BBB
Fludarabine
Fred Hutchinson Cancer Center
Phase 3BBB
Therapeutic Allogeneic Lymphocytes
University of Chicago
Phase 2BBB
Sargramostim
Virginia Commonwealth University
Phase 2BBB

View all 50 →

Same molecule, other indications

Ruxolitinib is also rated in:

primary myelofibrosisDormant
BBB
Indicative ·
73 / 100
View asset →
graft versus host diseaseDormant
BB
Indicative ·
70 / 100
View asset →
disease related to hematopoietic stem cell transplantDormant
BB
Indicative ·
70 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →